Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
16.99
+0.23 (1.37%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 | Upgrade
|
| Revenue Growth (YoY) | 66.92% | 12.12% | 11.84% | -7.17% | -23.03% | Upgrade
|
| Cost of Revenue | 37.41 | 37.64 | 40.62 | 63.39 | 193.66 | Upgrade
|
| Gross Profit | 70.05 | 26.74 | 16.8 | -12.05 | -138.35 | Upgrade
|
| Selling, General & Admin | 73.65 | 69.17 | 70.1 | 67.07 | 99.3 | Upgrade
|
| Operating Expenses | 73.65 | 69.17 | 70.45 | 67.07 | 99.3 | Upgrade
|
| Operating Income | -3.6 | -42.44 | -53.65 | -79.12 | -237.64 | Upgrade
|
| Interest Expense | -2.46 | -2.55 | -2.35 | -6.37 | -8.55 | Upgrade
|
| Interest & Investment Income | 10.27 | 4.98 | 9.02 | 6.74 | 2.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | -0.1 | 0.1 | -0.9 | -0.9 | Upgrade
|
| EBT Excluding Unusual Items | 4.11 | -40.1 | -46.88 | -79.65 | -245.08 | Upgrade
|
| Merger & Restructuring Charges | - | - | -2.39 | -12.84 | -20.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 2.71 | - | Upgrade
|
| Asset Writedown | - | -4.51 | - | - | - | Upgrade
|
| Other Unusual Items | 125.14 | - | - | -3.03 | - | Upgrade
|
| Pretax Income | 129.25 | -44.61 | -49.27 | -92.82 | -265.22 | Upgrade
|
| Income Tax Expense | 23.35 | 11.8 | 5.92 | 0.01 | -0.15 | Upgrade
|
| Earnings From Continuing Operations | 105.9 | -56.42 | -55.19 | -92.82 | -265.07 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 964.96 | 65.65 | Upgrade
|
| Net Income | 105.9 | -56.42 | -55.19 | 872.13 | -199.43 | Upgrade
|
| Net Income to Common | 105.9 | -56.42 | -55.19 | 872.13 | -199.43 | Upgrade
|
| Shares Outstanding (Basic) | 50 | 49 | 55 | 74 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 49 | 55 | 74 | 69 | Upgrade
|
| Shares Change (YoY) | 5.45% | -11.67% | -24.85% | 5.95% | 11.41% | Upgrade
|
| EPS (Basic) | 2.10 | -1.15 | -1.00 | 11.85 | -2.87 | Upgrade
|
| EPS (Diluted) | 2.06 | -1.15 | -1.00 | 11.85 | -2.87 | Upgrade
|
| Free Cash Flow | 238.5 | -11.87 | -29.49 | -187.56 | -211.26 | Upgrade
|
| Free Cash Flow Per Share | 4.63 | -0.24 | -0.53 | -2.55 | -3.04 | Upgrade
|
| Gross Margin | 65.19% | 41.53% | 29.26% | -23.46% | -250.12% | Upgrade
|
| Operating Margin | -3.35% | -65.91% | -93.43% | -154.09% | -429.65% | Upgrade
|
| Profit Margin | 98.54% | -87.63% | -96.11% | 1698.54% | -360.55% | Upgrade
|
| Free Cash Flow Margin | 221.93% | -18.43% | -51.35% | -365.29% | -381.96% | Upgrade
|
| EBITDA | -1.98 | -40.73 | -51.65 | -76.08 | -232.83 | Upgrade
|
| EBITDA Margin | -1.84% | -63.26% | -89.94% | -148.18% | - | Upgrade
|
| D&A For EBITDA | 1.63 | 1.71 | 2 | 3.04 | 4.81 | Upgrade
|
| EBIT | -3.6 | -42.44 | -53.65 | -79.12 | -237.64 | Upgrade
|
| EBIT Margin | -3.35% | -65.91% | -93.43% | -154.09% | - | Upgrade
|
| Effective Tax Rate | 18.07% | - | - | - | - | Upgrade
|
| Revenue as Reported | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 | Upgrade
|
| Advertising Expenses | 5.1 | 4.3 | 5.1 | 8 | 9.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.